Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. - Wikidata - awgldk - TriplyDB

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.

http://www.wikidata.org/entity/Q38169212

about

Precocious Alterations of Brain Oscillatory Activity in Alzheimer's Disease: A Window of Opportunity for Early Diagnosis and Treatment Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Anti-dementia medications: current prescriptions in clinical practice and new agents in progress Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models Presenilin 1 and Presenilin 2 Target γ-Secretase Complexes to Distinct Cellular Compartments.Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease.Pirinixic acids: flexible fatty acid mimetics with various biological activities.Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.α-Mangostin decreases β-amyloid peptides production via modulation of amyloidogenic pathway.Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances.Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease.Emerging amyloid and tau targeting treatments for Alzheimer's disease.Fused Morphlinopyrimidines and Methods of Use Thereof First in human study with a prodrug of galantamine: Improved benefit-risk ratio?Kinetics and Molecular Docking Studies of 6-Formyl Umbelliferone Isolated from Angelica decursiva as an Inhibitor of Cholinesterase and BACE1.Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer's disease.MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer's disease.Transcriptomic Analysis of Drosophila Mushroom Body Neurons Lacking Amyloid-β Precursor-Like Protein Activity.Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer’s Disease.A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay An accessible pharmacodynamic transcriptional biomarker for notch target engagement

P2860

Q26770751-42776211-7704-487E-81DC-96E659504E21 Q26784569-696AE6ED-727B-47CC-B227-52A269C19CCE Q26795400-788EF6F1-C0DE-43EC-9CA6-8D268FB0619E Q26829899-2AF2D22B-075E-4106-8F7A-35F2532D4C7B Q27305174-69C1F0A1-F3EB-425E-9C91-F0806FB40318 Q28601353-9ECF3C28-FCEF-422C-A384-ADF74C230D88 Q28829902-6BD86E7B-2E92-42C6-A5BC-A4D6C4A82C7D Q30780773-B655E70C-A5CF-4B3F-BCD9-72570E39450B Q34431008-ABA602F1-F47B-4B3D-B639-4203F72E33E6 Q34987506-257AC9A2-71D6-4E6E-9FBE-47074FC3AA98 Q35137488-5A8CEEEF-7F5F-41D2-82CA-A1971227D1BA Q35772984-0AD68C33-692A-4BD1-8D1B-C6DA3F9EC10C Q35813037-BD57BF91-0C7E-40E5-853E-8EE4F04CFBA6 Q36850925-990D0D3A-792B-4CFE-B7B1-F6ADCD282BD8 Q37665855-FD26E558-BEB1-4525-AEF9-2D890A4E8553 Q38574980-110DACFD-F133-44A0-BD8D-8623E5FED412 Q38641308-A1F57399-8BE4-498B-B689-F07C368AA16D Q38827287-B8F3C1F8-5381-44D1-8612-985F1E4379BD Q38936146-A73AA3B1-9589-46F2-B208-79D54A24BA1D Q39196662-534DB254-A1ED-47BF-8BB1-0F2C2DF71BE9 Q39296311-CCBD6517-1713-483B-8C44-391666D6E1AE Q42544939-220AA8AA-B468-41DB-B261-699F2D5A4D1C Q42689680-30DE829C-5B05-4A47-8800-FA46B5280BA1 Q47745925-3374071F-8E86-490C-AAC9-0098FD96D3C0 Q48503329-B619E677-2C5D-4EEC-A2FA-021EF0E56350 Q49491716-374F4505-59D6-4F1A-A7A1-9E161411B518 Q50244311-24A0E3E8-464F-4648-8D83-7BE74BB21F05 Q55405257-8AE6D545-BC3B-48FF-B70D-5962898DD179 Q57927766-3DE0D237-28B9-475D-8D3E-D242FFE81C11 Q58696563-9CEB9E71-04F8-4FBE-9E4D-BF232B22336E Q58862961-834BFEE1-7B23-4643-AE6B-FDCE2CE694DC

P2860

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.

http://www.wikidata.org/entity/Q38169212

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Potential novel targets for Al ...... bitors and related approaches.

@en

type

label

Potential novel targets for Al ...... bitors and related approaches.

@en

prefLabel

Potential novel targets for Al ...... bitors and related approaches.

@en

P1433

Q38169212-9C60AA92-08BB-46E2-8423-F5A4B2954B3E

P1476

Q38169212-1146B295-411F-4994-B1BA-985C51231EBB

P2093

Q38169212-2B3C1F7D-30EC-4E45-9764-79248DF665D1

Q38169212-89F40379-C278-4101-914C-6542F4BE6919

Q38169212-9055DF97-2B79-4CCF-9AB9-B407F5F70B70

Q38169212-9576DC66-5A4F-49C5-9FDB-F5A2BA25EC8B

Q38169212-99F26F13-40B4-41DD-B3D3-3FB0EF9E4903

Q38169212-D5C01E47-878C-4A9A-9825-A296E1C89ED7

Q38169212-D5DA1BAA-2E5B-406A-ABDA-0B6927F32365

Q38169212-D71A4FFC-209D-4DED-8280-C8F1E90DB418

Q38169212-E3682A58-BA5D-4EBF-BA2D-832FC1903BEC

P2860

Q38169212-0AC77432-D502-48A3-998E-A9C21839FD7F

Q38169212-12CD25EF-C96E-495D-BCF7-61ED6FFAEB38

Q38169212-259BFADC-2B3E-4BE2-ABE0-93C79F5E4490

Q38169212-2D1F48E7-CB18-448E-AD92-631CD1CE8763

Q38169212-312A355A-B883-4D83-A661-C54AD9DD6182

Q38169212-33F39920-95CA-4F93-99D9-0B40C83491F1

Q38169212-3F7B8AFD-C5C4-4991-94F5-B24E15ECA564

Q38169212-4743CD6E-B22D-4DE4-A72D-FC291A854F01

Q38169212-49F9162E-FC2B-458E-8CAB-30A0E9B7D58F

Q38169212-51D4D352-6962-4109-89A2-C7242E1B42DF

P304

Q38169212-9B90113D-CA9F-4FA3-BB76-CD8CED09C237

P31

Q38169212-CBB98432-579A-40DA-89FC-AF9018EBED8C

P356

Q38169212-A99047CE-B39A-4A90-9D14-2A0E79D55C27

P433

Q38169212-FB69233B-1069-420D-AD52-4305B6E69C36

P478

Q38169212-2E8B3D34-8D3E-4D6C-8D26-42EBB8F10159

P577

Q38169212-C06AF018-2AB2-4A62-8698-A2B909185C02

P5875

Q38169212-1401463C-3B54-43A5-B372-1D3EA1EFF401

P698

Q38169212-D77120D3-F204-49D5-B529-B6826F2E350E

P921

Q38169212-1D3CA05C-FDA9-4265-B753-E1ACC3F9C99C

P356

P1433

Journal of Clinical Pharmacy and Therapeutics

P1476

Potential novel targets for Al ...... bitors and related approaches.

@en

P2093

C H Tran

http://www.w3.org/2001/XMLSchema#string

D A Gajdosik

http://www.w3.org/2001/XMLSchema#string

E A Giunta

http://www.w3.org/2001/XMLSchema#string

E A Lessa

http://www.w3.org/2001/XMLSchema#string

E C Terak

http://www.w3.org/2001/XMLSchema#string

J A Mikulca

http://www.w3.org/2001/XMLSchema#string

R B Raffa

http://www.w3.org/2001/XMLSchema#string

S G Teklu

http://www.w3.org/2001/XMLSchema#string

V Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor

Patterns of brain activation in people at risk for Alzheimer's disease.

Potential novel targets for Alzheimer pharmacotherapy: I. Secretases.

P304

25-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12112

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259243890

http://www.w3.org/2001/XMLSchema#string

P698

24313554

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease